CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior...

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Bruton's tyrosine kinase inhibitors (BTKi) are effective treatments for chronic lymphocytic leukemia (CLL).
• Understanding resistance mechanisms to BTKi is crucial for improving patient outcomes.
• The role of microenvironmental factors in BTKi resistance requires further investigation.

Purpose of the Study:

• To investigate the role of CD49d expression in predicting response to BTKi therapy in CLL patients.
• To assess the impact of CD49d and VLA-4 activation on CLL cell behavior and signaling pathways.
• To evaluate the prognostic significance of CD49d expression, including bimodal patterns, in CLL patients treated with BTKi.

Main Methods:

• CD49d expression, VLA-4 activation, and tumor transcriptomes were analyzed in CLL patients treated with acalabrutinib.
• Clinical responses were assessed in combined cohorts of acalabrutinib- and ibrutinib-treated patients.
• RNA sequencing and gene set enrichment analysis were employed to compare CD49d-positive and CD49d-negative CLL cases.

Main Results:

• CD49d+ CLL cases exhibited increased constitutive NF-κB and JAK-STAT signaling, enhanced survival, adhesion, and migratory capacity.
• BTKi treatment inhibited constitutive VLA-4 activation but not BCR or CXCR4-mediated activation.
• Patients with homogeneous or bimodal CD49d expression had a significantly shorter time to progression compared to CD49d-negative cases.

Conclusions:

• CD49d/VLA-4 is identified as a microenvironmental factor contributing to BTKi resistance in CLL.
• The prognostic value of CD49d in CLL is enhanced by considering bimodal expression patterns.
• Targeting CD49d or related pathways may offer new strategies to overcome BTKi resistance.